Reviewed by Michael Gill, B. Sc.
25 Durlaza Clinical Trials Near Me
Top Cities for Durlaza Clinical Trials
Durlaza Clinical Trials by Phase of Trial
Phase < 1 Durlaza Clinical Trials
15Active Durlaza Clinical Trials
10Number of Unique Treatments
13Number of Active Locations
Low dose ASAAspirin 80 mg EC TabAspirinAspirin 81 mgAspirinPGD2AtorvastatinLow-dose aspirin
Most Recent Durlaza Clinical Trials

What Are Durlaza Clinical Trials?

Durlaza (Aspirin Capsules) clinical trials are research studies that test if Durlaza is safe and effective in people. Aspirin is a drug that is being studied for the treatment of heart disease and stroke. However, standard treatments of this drug include relief of symptoms from pain, fever, acute coronary syndrome, ischemic stroke, and transient ischemic attacks.

Why Is Durlaza Being Studied in Clinical Trials?

Durlaza is being studied in clinical trials because researchers are testing its effectiveness in cardiovascular diseases. There are also studies testing to see if Aspirin is better than anticoagulation in cervical artery dissection.

Aside from treatment, studies are also being conducted to see if there are any adverse effects of taking populations off of Durlaza without any clinical indication.

There is extensive use of Aspirin tablets. Thus, there are many different types of applications that Durlaza can be used. However, the main clinical testing is for blood clotting and heart-related issues.

How Does Durlaza Work?

The mechanism of action for Durlaza is still being studied. However, some scientists believe Durlaza works by inhibiting the cyclooxygenase (COX) enzyme. This enzyme is responsible for the production of prostaglandins and thromboxanes. Prostaglandins are known to promote inflammation, while thromboxanes are known to promote clotting. Therefore, by inhibiting the COX enzyme, Durlaza theoretically reduces both inflammation and clotting.

Before Durlaza, common treatments were either anti-inflammatory drugs or anticoagulants. Durlaza is unique because it is a single drug that inhibits both processes. This makes Durlaza a very promising treatment option for heart disease and stroke.

What Are Some of The Breakthrough Clinical Trials Involving Durlaza?

Here are some of the breakthrough Clinical Trials involving Aspirin:

2013: This early 2013 study shows that patients with Transient Ischemic Attacks (TIA) or Minor Ischemic Stroke showed more effectiveness to Aspirin and Clopidogrel than with Aspirin use alone. Additionally, they found that using Aspirin did not increase the risk of hemorrhage, which is essential to note.

2020: This study tests to see if Durlaza paired with Ticagrelor or Aspirin alone can improve outcomes in patients with an ischemic stroke. Results found that Ticagrelor-Aspirin for stroke or death was lower in this group. However, the Ticagrelor group had more severe bleeding.

2021: A polypill that includes statins, blood-pressure-lowering drugs, and Aspirin was tested to see if it can reduce the risk of cardiovascular disease. The findings found that the polypill effectively lowered the incidence of cardiovascular events in patients at intermediate cardiovascular risks versus a placebo polypill.

Who Are The Key Opinion Leaders On Durlaza Clinical Trial Research?

Dr. Peter M. Rothwell is a Professor of Neurological Sciences and Consultant Neurologist at the University of Oxford in the United Kingdom. He is also the Lead for Prevention of Stroke at the Oxford University Hospitals NHS Foundation Trust.

Dr. John A. Eikelboom is a Staff Cardiologist and Senior Investigator at the Population Health Research Institute (PHRI) of McMaster University and Hamilton Health Sciences in Hamilton, Ontario, Canada.

Dr. Nancy R. Cook is a Professor of Medicine at Brigham and Women’s Hospital and Harvard Medical School in Boston, Massachusetts.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 20th, 2021

Last Reviewed: November 20th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9:CD013825. doi: 10.1002/14651858.CD013825.pub2. Review. https://pubmed.ncbi.nlm.nih.gov/344733432 Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2. https://pubmed.ncbi.nlm.nih.gov/344733433 Natale P, Palmer SC, Saglimbene VM, Ruospo M, Razavian M, Craig JC, Jardine MJ, Webster AC, Strippoli GF. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev. 2022 Feb 28;2:CD008834. doi: 10.1002/14651858.CD008834.pub4. Review. https://pubmed.ncbi.nlm.nih.gov/352247304 Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005 Apr;3(4):692-4. https://pubmed.ncbi.nlm.nih.gov/158423545 Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30. https://pubmed.ncbi.nlm.nih.gov/197178466 Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract. 2004 May;10(2):307-12. https://pubmed.ncbi.nlm.nih.gov/151893967 Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL; American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018 Mar;49(3):e46-e110. doi: 10.1161/STR.0000000000000158. Epub 2018 Jan 24. Review. Erratum in: Stroke. 2018 Mar;49(3):e138. Stroke. 2018 Apr 18;:. https://pubmed.ncbi.nlm.nih.gov/293673348 Middleton P, Shepherd E, Gomersall JC. Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period. Cochrane Database Syst Rev. 2021 Mar 29;3:CD001689. doi: 10.1002/14651858.CD001689.pub4. https://pubmed.ncbi.nlm.nih.gov/337799869 Mikolajewska A, Fischer AL, Piechotta V, Mueller A, Metzendorf MI, Becker M, Dorando E, Pacheco RL, Martimbianco ALC, Riera R, Skoetz N, Stegemann M. Colchicine for the treatment of COVID-19. Cochrane Database Syst Rev. 2021 Oct 18;10:CD015045. doi: 10.1002/14651858.CD015045. Review. https://pubmed.ncbi.nlm.nih.gov/3465801410 Mikolajewska A, Fischer AL, Piechotta V, Mueller A, Metzendorf MI, Becker M, Dorando E, Pacheco RL, Martimbianco ALC, Riera R, Skoetz N, Stegemann M. Colchicine for the treatment of COVID-19. Cochrane Database Syst Rev. 2021 Oct 18;10(10):CD015045. doi: 10.1002/14651858.CD015045. https://pubmed.ncbi.nlm.nih.gov/34658014